Teva Pharm Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA PHARM, and when can generic versions of TEVA PHARM drugs launch?
TEVA PHARM has three hundred and twenty approved drugs.
There are thirty-two US patents protecting TEVA PHARM drugs. There are forty-four tentative approvals on TEVA PHARM drugs.
There are four hundred and thirty-six patent family members on TEVA PHARM drugs in thirty-six countries and nine hundred and sixteen supplementary protection certificates in eighteen countries.
Summary for Teva Pharm
International Patents: | 436 |
US Patents: | 32 |
Tradenames: | 268 |
Ingredients: | 260 |
NDAs: | 320 |
Patent Litigation for Teva Pharm: | See patent lawsuits for Teva Pharm |
PTAB Cases with Teva Pharm as petitioner: | See PTAB cases with Teva Pharm as petitioner |
Drugs and US Patents for Teva Pharm
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Pharms Usa | EPTIFIBATIDE | eptifibatide | INJECTABLE;INJECTION | 090854-001 | Jun 12, 2015 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Teva Pharms Usa Inc | LEVOTHYROXINE SODIUM | levothyroxine sodium | CAPSULE;ORAL | 211369-003 | Apr 16, 2021 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Teva Pharms Usa | MORPHINE SULFATE | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 202718-001 | Dec 29, 2014 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Teva Pharm | ARMONAIR DIGIHALER | fluticasone propionate | POWDER;INHALATION | 208798-005 | Feb 20, 2020 | RX | Yes | No | 11,173,259*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Teva Pharm | AIRDUO DIGIHALER | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-006 | Jul 12, 2019 | RX | Yes | No | 11,344,685*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Teva Pharm
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Teva Pharm | AIRDUO DIGIHALER | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-004 | Jul 12, 2019 | 8,006,690 | ⤷ Try a Trial |
Teva Pharm | AIRDUO RESPICLICK | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-002 | Jan 27, 2017 | 6,446,627 | ⤷ Try a Trial |
Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-002 | Jan 27, 2017 | 6,748,947 | ⤷ Try a Trial |
Teva Pharms Intl | AMRIX | cyclobenzaprine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021777-002 | Feb 1, 2007 | 7,790,199 | ⤷ Try a Trial |
Teva Pharm | AIRDUO RESPICLICK | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-003 | Jan 27, 2017 | 6,871,646 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TEVA PHARM drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Extended-release Capsule | 15 mg and 30 mg | ➤ Subscribe | 2008-08-11 |
➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-02-26 |
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
➤ Subscribe | for Injection | 3.5 mg/vial | ➤ Subscribe | 2016-10-26 |
➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-01-29 |
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
Premature patent expirations for TEVA PHARM
Expiration due to failure to pay maintenance fee
Patent Number | Expiration Date |
---|---|
⤷ Try a Trial | ⤷ Try a Trial |
International Patents for Teva Pharm Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Mexico | 2016004316 | ⤷ Try a Trial |
Denmark | 2177223 | ⤷ Try a Trial |
South Korea | 101718674 | ⤷ Try a Trial |
Eurasian Patent Organization | 201690641 | ⤷ Try a Trial |
China | 110461394 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Teva Pharm Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1663240 | 1590057-4 | Sweden | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF RILPIVIRINE, OR A PHARMACEUTICAL LY ACCEPTABLE SALT OF RILPIVIRINE, INCLUDING THE HYDROCHLORIDE SALT OF RILPIVIRINE, AND TENOFOVIR DISOPROXIL, IN PARTICULAR TENOFOVIR DISOPROXIL FUMARATE, AND EMTRICITABINE; REG. NO/DATE: EU/1/11/737 20111128 |
2203462 | SPC/GB14/078 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: SOFOSBUVIR; REGISTERED: UK EU/1/13/894/001 20140117; UK EU/1/13/894/002 20140117 |
1301519 | CR 2016 00012 | Denmark | ⤷ Try a Trial | PRODUCT NAME: TENOFOVIRALAFENAMID ELLER ET SALT ELLER SOLVAT DERAF, I SAERDELESHED TENOFOVIRALAFENAMIDFUMARAT; REG. NO/DATE: EU/1/15/1061/001-002 20151123 |
1519731 | 92269 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE |
0240228 | 2000C/015 | Belgium | ⤷ Try a Trial | PRODUCT NAME: QUETIAPINE FUMARAT (EQUIV. MET 25MG QUETIAPINE BASE); REGISTRATION NO/DATE: 624 S 309 F 3 20000207; FIRST REGISTRATION: GB PL 12619/0113 19970731 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.